TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17587710

Group type: EXPERIMENTAL
Intervention: Serum from patients with coronary aneurysms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin plus aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients who developed giant aneurysms >8 mm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum activity of stimulating HUVEC proliferation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: COMPARATOR
Intervention: Febrile controls
Number of subjects: 0
Study: 15292523

Group type: EXPERIMENTAL
Intervention: Computed total body Th contents and daily urinary excretions in occupational workers
Number of subjects: 5

Group type: COMPARATOR
Intervention: Theoretically computed Th contents in lungs, skeleton and liver
Number of subjects: 5

Group type: COMPARATOR
Intervention: Experimentally measured Th contents in lungs, skeleton and liver
Number of subjects: 5
Study: 11355096

Group type: EXPERIMENTAL
Intervention: Composite (Tetric, Vivadent)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Polyacid‐modified resin composite (Dyract, Dentsply)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer cement (Fuji II LC, GC)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Resin‐modified glass ionomer cement (Photac‐Fil, Espe)
Number of subjects: 197
Study: 9346426

Group type: EXPERIMENTAL
Intervention: Acetazolamide (Acz) administration
Number of subjects: 125

Group type: COMPARATOR
Intervention: Physiologic saline (placebo) administration
Number of subjects: 125
Study: 8389536

Group type: EXPERIMENTAL
Intervention: Culture preparations of skin specimens from primary EM patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Culture preparations of skin specimens from secondary EM patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Serologic findings in primary EM patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Clinical features in secondary EM patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Liver enzyme profiles in secondary EM patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Heart conditions in secondary EM patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Tick bite recall in all patients
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Isomorphic nonresponse in secondary EM
Number of subjects: 28
Study: 3518312

Group type: EXPERIMENTAL
Intervention: Prednisolone 1.5 mg/kg bw daily, taken in the morning once every three days for 30-45 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prednisolone 30-60 mg daily
Number of subjects: 0
Study: 31954837

Group type: EXPERIMENTAL
Intervention: Stepwise CMD risk assessment followed by individualized treatment
Number of subjects: 0
Study: 29444778

Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin Pill (SBP) - 1-2 pills three times daily for at least 6 months
Number of subjects: 440

Group type: COMPARATOR
Intervention: Placebo (SBP placebo)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Shexiang Baoxin Pill (SBP)
Number of subjects: 440
Study: 26727154

Group type: EXPERIMENTAL
Intervention: Home-use laser device combined with antioxidant facial treatment for 12 weeks followed by 2-week regression period
Number of subjects: 49

Group type: COMPARATOR
Intervention: Home-use laser device alone for 12 weeks followed by 2-week regression period
Number of subjects: 49

Group type: COMPARATOR
Intervention: Support materials used on one side for 10 weeks
Number of subjects: 49
Study: 25128283

Group type: EXPERIMENTAL
Intervention: Informed participants (prior knowledge of the stolen item)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guilty-informed participants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guilty-naïve participants
Number of subjects: 0
Study: 22045433

Group type: EXPERIMENTAL
Intervention: Solid phase microextraction (SPME)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Plasma protein precipitation (PPP)
Number of subjects: 10
Study: 19385024

Group type: EXPERIMENTAL
Intervention: Restrained eating behaviour
Number of subjects: 33

Group type: COMPARATOR
Intervention: Unrestrained eating behaviour
Number of subjects: 33
Study: 17461308

Group type: EXPERIMENTAL
Intervention: Preoperative localisation with sestamibi scintigraphy and ultrasonography (group I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No preoperative localisation (group II)
Number of subjects: 100
Study: 15056389

Group type: EXPERIMENTAL
Intervention: Physical activity intervention (details not specified)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 12057615

Group type: EXPERIMENTAL
Intervention: Two dose schedule (0 and 6 months) using Twinrix paediatric (360 EL.U HAV antigen/10 microg HBs antigen)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Three dose schedule (0, 1 and 6 months) using adult formulation (720 EL.U HAV antigen/20 microg HBs antigen)
Number of subjects: 100
Study: 7916546

Group type: EXPERIMENTAL
Intervention: Somatostatin (SST) administered intrathecally and epidurally, mean daily dose 1,252 μg (range 250-3,000 μg), mean duration 11.3 days
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Somatostatin (SST)
Number of subjects: 8
Study: 2589241

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 120
Study: 179223

Group type: EXPERIMENTAL
Intervention: Monotherapy with Adriamycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneously given polychemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polychemotherapy
Number of subjects: 0
Study: 31472154

Group type: EXPERIMENTAL
Intervention: Pleural manometry
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normal PEL
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Post-drainage chest radiograph
Number of subjects: 70

Group type: COMPARATOR
Intervention: Post-thoracentesis chest radiograph
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Discordance between post-procedural chest radiograph and pleural manometry results
Number of subjects: 70
Study: 27979753

Group type: EXPERIMENTAL
Intervention: HC2 intervention arm CCCs receive implementation of a daily curricula for teachers/parents, children, snack, beverage, physical activity, and screen time policies, and technical assistance with menu modifications.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Attention control safety curriculum
Number of subjects: 24
Study: 26743856

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice a day
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 703

Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg twice a day (in patients with EGFR mutations)
Number of subjects: 703

Group type: COMPARATOR
Intervention: Placebo (in patients with EGFR mutations)
Number of subjects: 703
Study: 23493968

Group type: EXPERIMENTAL
Intervention: Pregnant women with asthma
Number of subjects: 285

Group type: COMPARATOR
Intervention: Pregnant women without asthma
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Laboratory-confirmed viral infection in women with asthma
Number of subjects: 285
Study: 21623001

Group type: EXPERIMENTAL
Intervention: Dynamic humeral centering (DHC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Non-specific mobilisation (control)
Number of subjects: 69
Study: 19651013

Group type: EXPERIMENTAL
Intervention: Modified Hong Kong procedure without instrumentation (Group A)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Modified Hong Kong procedure with additional instrumentation (Group B)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Comparison between Group A and Group B
Number of subjects: 62
Study: 16424116

Group type: EXPERIMENTAL
Intervention: Soluble fiber supplement (3 g/d)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 15098638

Group type: EXPERIMENTAL
Intervention: Pharmacist consult clinic
Number of subjects: 126
Study: 11089824

Group type: EXPERIMENTAL
Intervention: Peer counselling (15 home-based counselling visits, including two visits in the last trimester and three early postpartum visits)
Number of subjects: 726

Group type: EXPERIMENTAL
Intervention: Peer counselling
Number of subjects: 726

Group type: COMPARATOR
Intervention: Control group (no peer counselling)
Number of subjects: 726
Study: 9624542

Group type: EXPERIMENTAL
Intervention: Single-dose fosfomycin trometamol
Number of subjects: 547

Group type: COMPARATOR
Intervention: 5-day course of trimethoprim
Number of subjects: 547

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 547
Study: 7836192

Group type: EXPERIMENTAL
Intervention: Intense Training (IT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate Training (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 2968374

Group type: EXPERIMENTAL
Intervention: Trioxsalen bath-PUVA treatment (0.2 mg/L solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methoxsalen bath-PUVA treatment (0.4 mg/L solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methoxsalen bath-PUVA treatment with UVA doses similar to trioxsalen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trioxsalen bath-PUVA treatment (control for methoxsalen)
Number of subjects: 0
Study: 29843525

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation plus inspiratory muscle training (PR + IMT group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation group (PR group)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study: 28477440

Group type: EXPERIMENTAL
Intervention: Intravitreous fluocinolone acetonide implant
Number of subjects: 215

Group type: COMPARATOR
Intervention: Systemic corticosteroids and immunosuppression
Number of subjects: 215
Study: 23020135

Group type: EXPERIMENTAL
Intervention: Maternal zinc supplementation
Number of subjects: 259

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 259
Study: 23908551

Group type: EXPERIMENTAL
Intervention: Diclofenac 4% spray gel
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 232
Study: 21284481

Group type: EXPERIMENTAL
Intervention: Exenatide (5 μg b.d. × 4 weeks followed by 10 μg b.d. × 12 weeks)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 18035519

Group type: EXPERIMENTAL
Intervention: Residential cognitive therapy (RCT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Residential interpersonal therapy (RIPT)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both RCT and RIPT
Number of subjects: 80
Study: 16425182

Group type: EXPERIMENTAL
Intervention: 125 microg/m(2) GM-CSF subcutaneously three times a week until clinical progression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 250 microg/m(2) GM-CSF subcutaneously three times a week until clinical progression
Number of subjects: 0
Study: 12692706

Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10843245

Group type: EXPERIMENTAL
Intervention: Hemodialysis
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: CAPD
Number of subjects: 43

Group type: COMPARATOR
Intervention: Non-dialyzed ESKD patients
Number of subjects: 43

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 43
Study: 9337505

Group type: EXPERIMENTAL
Intervention: JOBS II intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inoculation against setbacks (part of JOBS II intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 7899626

Group type: EXPERIMENTAL
Intervention: Combined intra- and extra-articular plasty (iliotibial band tenodesis)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Isolated intra-articular semitendinosus reconstruction
Number of subjects: 32
Study: 3314645

Group type: EXPERIMENTAL
Intervention: 10 mg phenoxybenzamine orally
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 29573055

Group type: EXPERIMENTAL
Intervention: Cross-matched pRBCs
Number of subjects: 48

Group type: COMPARATOR
Intervention: Noncross-matched pRBCs
Number of subjects: 48
Study: 25728984

Group type: EXPERIMENTAL
Intervention: IA cisplatin 150 mg/m²
Number of subjects: 237

Group type: COMPARATOR
Intervention: IV cisplatin 100 mg/m²
Number of subjects: 237
Study: 24272830

Group type: EXPERIMENTAL
Intervention: Rating and ranking values clarification method
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Balance sheet values clarification method
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Discrete choice experiment (DCE) values clarification method
Number of subjects: 920

Group type: EXPERIMENTAL
Intervention: Fecal occult blood test (FOBT)
Number of subjects: 920

Group type: COMPARATOR
Intervention: No screening
Number of subjects: 920
Study: 23773895

Group type: EXPERIMENTAL
Intervention: Nordic walking
Number of subjects: 54

Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation care
Number of subjects: 54
Study: 19913821

Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation
Number of subjects: 33
Study: 19999230

Group type: EXPERIMENTAL
Intervention: Nitrous oxide free group
Number of subjects: 200

Group type: COMPARATOR
Intervention: N2O group
Number of subjects: 200
Study: 16627439

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 14616255

Group type: EXPERIMENTAL
Intervention: 1 mg of 17beta‐estradiol plus 0.5 mg of norethisterone acetate
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 2.5 mg tibolone
Number of subjects: 44
Study: 10771224

Group type: EXPERIMENTAL
Intervention: ICRS implantation (Intacs) in bilateral treatment group
Number of subjects: 134

Group type: COMPARATOR
Intervention: ICRS implantation (Intacs) in unilateral treatment group
Number of subjects: 134
Study: 9190245

Group type: EXPERIMENTAL
Intervention: Ambrosol
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 1568575

Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg/kg per hour)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous saline (placebo)
Number of subjects: 10
Study: 3911362

Group type: EXPERIMENTAL
Intervention: diethyl‐carbamazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: ivermectin
Number of subjects: 0
Study: 29925494

Group type: EXPERIMENTAL
Intervention: High-tailored story intervention
Number of subjects: 792

Group type: COMPARATOR
Intervention: Low-tailored story intervention
Number of subjects: 792

Group type: COMPARATOR
Intervention: Cigarettes smoked per day
Number of subjects: 792

Group type: COMPARATOR
Intervention: Education level
Number of subjects: 792
Study: 27043681

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (once-daily) from admission day until discharge
Number of subjects: 42

Group type: COMPARATOR
Intervention: No atorvastatin treatment until discharge, atorvastatin started after discharge
Number of subjects: 42
Study: 25293900

Group type: EXPERIMENTAL
Intervention: First aid training course
Number of subjects: 500
Study: 23045348

Group type: EXPERIMENTAL
Intervention: BoNT-A injection into the soleus muscle
Number of subjects: 14
Study: 20466293

Group type: EXPERIMENTAL
Intervention: Comprehensive genetic counseling (experimental group)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control group (no comprehensive genetic counseling)
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Anxiety and depression levels (both groups)
Number of subjects: 193
Study: 18712779

Group type: EXPERIMENTAL
Intervention: Non-parametric multiple imputation method for competing risks failure times
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Kaplan-Meier imputation method for censoring times
Number of subjects: 0
Study: 16722852

Group type: EXPERIMENTAL
Intervention: Tielle hydropolymer dressings
Number of subjects: 6993
Study: 12848776

Group type: EXPERIMENTAL
Intervention: 30 mg DEX hydro-bromide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 60 mg DEX hydro-bromide
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 30 mg DEX hydro-bromide preceded at 1 h by quinidine HCl (50 mg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10098822

Group type: EXPERIMENTAL
Intervention: Harassment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 8906205

Group type: EXPERIMENTAL
Intervention: Aprotinin (G-2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (G-1)
Number of subjects: 0
Study: 1797506

Group type: COMPARATOR
Intervention: 125I‐labeled human soluble insulin (Actrapid HM U‐100)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Dimeric analogue AspB10
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Analogue AspB28
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Monomeric analogue AspB9, GluB27
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Hexameric human insulin
Number of subjects: 7
Study: 6817370

Group type: EXPERIMENTAL
Intervention: Clorgyline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pargyline
Number of subjects: 0
Study: 31889500

Group type: EXPERIMENTAL
Intervention: Myositis patients
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 108

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 108
Study: 27896952

Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Radical mastectomy
Number of subjects: 255

Group type: COMPARATOR
Intervention: Healthy individuals (control group)
Number of subjects: 255
Study: 27499448

Group type: EXPERIMENTAL
Intervention: 600mg DHA per day
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Universal supplementation with 600mg/d DHA
Number of subjects: 197
Study: 24918788

Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 0
Study: 21659848

Group type: EXPERIMENTAL
Intervention: 8% pirfenidone (PFD) gel administered topically 3 times a day during 6 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Pressure therapy
Number of subjects: 33
Study: 19010549

Group type: EXPERIMENTAL
Intervention: Visual impairment (better eye <6/18) after best correction
Number of subjects: 1375

Group type: EXPERIMENTAL
Intervention: Blindness (better eye <3/60) after best correction
Number of subjects: 1375
Study: 17447977

Group type: EXPERIMENTAL
Intervention: NB-UVB
Number of subjects: 50

Group type: COMPARATOR
Intervention: PUVA
Number of subjects: 50
Study: 15246726

Group type: EXPERIMENTAL
Intervention: Intracoronary transfer of autologous bone‐marrow cells
Number of subjects: 60

Group type: COMPARATOR
Intervention: Optimum postinfarction medical treatment (Control)
Number of subjects: 60
Study: 12042287

Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound scan by a single ultrasonographer
Number of subjects: 27
Study: 9891896

Group type: EXPERIMENTAL
Intervention: 3.75 mg midazolam
Number of subjects: 23

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 23
Study: 7698046

Group type: EXPERIMENTAL
Intervention: RGD peptide matrix (Argidene Gel) applied topically twice weekly for up to 10 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (topical saline) plus standard care
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: RGD peptide matrix
Number of subjects: 65
Study: 2260915

Group type: EXPERIMENTAL
Intervention: Estradiol or its conjugate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Estrogens (general)
Number of subjects: 8
Study: 25030

Group type: EXPERIMENTAL
Intervention: Undiluted diazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diluted diazepam (10 mg diluted to 20-40 ml)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam (undiluted or diluted)
Number of subjects: 0
Study: 31776027

Group type: EXPERIMENTAL
Intervention: Tdap vaccine
Number of subjects: 601

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 601
Study: 31263553

Group type: EXPERIMENTAL
Intervention: Simplified training curriculum and pictorial tools for RECOs
Number of subjects: 152

Group type: COMPARATOR
Intervention: Control group (standard tools and training)
Number of subjects: 152
Study: 27699618

Group type: EXPERIMENTAL
Intervention: Multidisciplinary implementation strategy
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Training sessions
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Implementation strategy
Number of subjects: 128
Study: 26444157

Group type: EXPERIMENTAL
Intervention: Unna Boot
Number of subjects: 18

Group type: COMPARATOR
Intervention: Elastic bandage
Number of subjects: 18
Study: 22959478

Group type: EXPERIMENTAL
Intervention: Rapamycin (16 mg oral dose)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (no rapamycin)
Number of subjects: 6
Study: 21752315

Group type: EXPERIMENTAL
Intervention: Deferasirox (DFX) treatment at 30-40 mg/kg•d
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (deferoxamine and deferiprone)
Number of subjects: 24
Study: 20145794

Group type: EXPERIMENTAL
Intervention: Bipolar sealer
Number of subjects: 69

Group type: COMPARATOR
Intervention: Standard electrocautery
Number of subjects: 69
Study: 17437788

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,250 mg/m² on days 1 and 8 plus 70 mg/m² cisplatin or carboplatin (AUC 5) on day 1, repeated every 21 days for 6 cycles
Number of subjects: 23
Study: 16342089

Group type: EXPERIMENTAL
Intervention: AZD3582 375 mg twice a day
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: AZD3582 750 mg twice a day
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: AZD3582 125 mg twice a day
Number of subjects: 672

Group type: COMPARATOR
Intervention: Rofecoxib 25 mg once a day
Number of subjects: 672

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 672

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice a day
Number of subjects: 672
Study: 12475455

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty with stenting (PCI)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass grafting (surgery)
Number of subjects: 102
Study: 9619746

Group type: EXPERIMENTAL
Intervention: 5FU + IFNalpha-2a
Number of subjects: 205

Group type: COMPARATOR
Intervention: 5FU alone
Number of subjects: 205
Study: 10155207

Group type: EXPERIMENTAL
Intervention: Matching as a surrogate for randomization
Number of subjects: 0